pazopanib hydrochloride
Drug Details
- Generic Name
- pazopanib hydrochloride
- Brand Names
- VOTRIENT, pazopanib
- Application Number
- NDA022465
- Sponsor
- Novartis Pharmaceuticals Corporation
- NDC Codes
- 5
- Dosage Forms
- TABLET, FILM COATED
- Routes
- ORAL
- Active Ingredients
- PAZOPANIB HYDROCHLORIDE
Indications and Usage
1 INDICATIONS AND USAGE Pazopanib tablets are a kinase inhibitor indicated for the treatment of adults with: advanced renal cell carcinoma (RCC). ( 1.1 ) advanced soft tissue sarcoma (STS) who have received prior chemotherapy. ( 1.2 ) Limitations of Use: The efficacy of pazopanib tablets for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. 1.1 Renal Cell Carcinoma Pazopanib tablets are indicated for the treatment of adults with advanced renal cell carcinoma (RCC). 1.2 Soft Tissue Sarcoma Pazopanib tablets are indicated for the treatment of adults with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. Limitations of Use: The efficacy of pazopanib tablets for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated.